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Abstract
Background
Whether diabetic patients without a history of coronary heart disease (CHD) have the same
risk of CHD events as non-diabetic patients with a history of CHD remains controversial.
This study aimed to determine whether type 2 diabetes mellitus (T2DM) is a coronary heart
disease (CHD) equivalent in the need for coronary revascularization procedures (RVs) in
the Korean population.
Methodology/Principal Findings
We followed 2,168,698 subjects who had oral anti-diabetic drugs (OADs)-taking T2DM in
2008 and/or CHD in 2007–2008 (i.e., recent CHD). We used systematic datasets from the
nationwide claims database of the Health Insurance Review and Assessment service of
Korea, which is representative of the whole population of Korea, from January 2007 to De-
cember 2012. The primary study endpoint was the development of need for RVs (i.e., inci-
dent CHD) after January 2009 among three groups based on their status of T2DM and
recent CHD, i.e., T2DM only, recent CHD only, and both T2DM and recent CHD. After ad-
justment for age and sex, patients with recent CHD only had 2.14 times the risk of incident
CHD (95% CI, 2.11–2.18, P<0.001) compared with patients with T2DM only. Patients with
both T2DM and recent CHD demonstrated approximately 2-fold increased risk of incident
CHD compared with subjects with recent CHD only (95% CI, 1.75-1.82), while 4-fold
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increased risk compared with subjects with T2DM only (95% CI, 3.71-3.87). The risk of inci-
dent CHD also differed according to sex and age.
Conclusions/Significance
This analysis of data from the nationwide claims database revealed that T2DM did not have
a recent CHD equivalent risk in the Korean population. These results suggest that an appro-
priate strategy for the CHD risk stratification in diabetic patients should be adopted to man-
age this population.
Introduction
Although type 2 diabetes mellitus (T2DM) is a well-known risk factor for cardiovascular dis-
ease (CVD) and is associated with a 2- to 4-fold increase in the risk of developing coronary
heart disease (CHD) [1–3], the magnitude of that risk recently faces challenges. In 1998, Haff-
ner SM et al. demonstrated that subjects with T2DM but without prior myocardial infarction
(MI) had a risk for fatal cardiovascular events equivalent to subjects without T2DM who had
survived an MI [4].
Since the landmark study by Haffner SM et al. described above, numerous reports have also
supported the concept of diabetes as a CHD risk equivalent [5–10], while others have refuted it
[11–16].As a result of these inconsistent outcomes, a meta-analysis was recently performed to
further test the concept of diabetes as a CHD equivalent [17]. The analysis did not support the
hypothesis that diabetes is a CHD equivalent and suggested that new appropriate patient CHD
risk estimates should be adopted in treating patients with T2DM rather than a ‘blanket’ ap-
proach of cardio protective drugs [17]. However, most studies were based mainly on Caucasian
populations, and there has been minimal research in Asian populations, including in Korea.
There are striking ethnic differences in CHD risk [18]. Furthermore, Asian countries including
Korea are emerging as the epicenter of the epidemic of diabetes due to their large populations
and rapid economic growth [19]. As the prevention and treatment of CHD is an enormous
medical and socio-economic problem, this issue of T2DM as a CHD equivalent is of consider-
able importance from an economic perspective as well as from a therapeutic perspective.
The present study aimed to clarify whether T2DM is a recent CHD equivalent in the need
for coronary revascularization procedures (RVs) in a Korean population through analysis of
nationwide population data from the Korean National Claim Registry in which all Koreans are
obliged to enroll.
Subjects and Methods
Data sources
Systematic datasets from the nationwide claims database of the Health Insurance Review and
Assessment (HIRA) service of Korea from January 2007 to December 2012 were used for the
analysis. In Korea, 97% of the population is obliged to enroll in the Korean National Health In-
surance Program. Patients pay approximately from 5% to 30% of total medical costs to clinics
or hospitals, although some services are not covered by insurance, such as cosmetic surgery
and some unproven therapies. Clinics and hospitals then submit claims for inpatient and out-
patient care, including data on diagnoses [as determined by the International Classification of
Diseases, 10th revision (ICD-10)], procedures, prescription records, demographic information,
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and direct medical costs, to obtain reimbursement for total medical costs (ranged from 70% to
95%). The remaining 3% of the population not insured by the Korean National Health Insur-
ance Program are either covered by another Medical Aid Program or are temporary or illegal
residents. These claims are also reviewed by HIRA, and thus, virtually all information pertain-
ing to patients and their medical records is available in the Korean HIRA database. The cohort
of patients aged 40 to 79 years in January 2009 was recruited from the HIRA service database,
which provided a representative dataset of the whole population of Korea. This dataset has
been previously used to conduct epidemiological studies in Korea [20–22], and the background
and configuration process of this dataset was described elsewhere in detail [23]. As all data
were analyzed anonymously, consent was not specifically obtained. The institutional review
board of the Asan Medical Center (Seoul, Republic of Korea) approved this study (IRB No.
2014–0815).
Definition of prevalent T2DM
T2DM was defined as being prevalent if subjects were taking oral anti-diabetic drugs (OADs)
for more than 90 days in the year of 2008. T2DM was further classified into two categories:
‘new-onset T2DM’ if there were no claims in the database relating to OADs in 2007 and ‘estab-
lished T2DM’ in the remaining cases.
Ascertainment of recent CHD and need for coronary RVs
The primary study endpoint was the development of need for coronary RVs after January 2009
among three groups based on their status of T2DM and recent CHD. The three groups were
T2DM only, recent CHD only, and both T2DM and recent CHD. We ascertained the status of
recent CHD using records of the Korean HIRA database from 2007 to 2008; earlier health rec-
ords could not be obtained due to the abrogation of the database according to government poli-
cy. We defined recent CHD based on the codes for coronary RVs including percutaneous
coronary intervention (PCI) and/or coronary artery bypass graft (CABG). One or more proce-
dure codes of PCI (M6551-2, M6561-4, and M6571-2) and CABG (O1641-2, O1647, OA641-2,
and OA647) were required for inclusion in this study. In addition, recent CHD was defined by
using the hospital discharge databases of the HIRA service [ICD-10 codes I20 (angina pecto-
ris), I21 (ST elevation and non-ST elevation myocardial infarction), I22 (subsequent ST eleva-
tion and non-ST elevation myocardial infarction), I23 (certain current complications following
ST elevation and non-ST elevation myocardial infarction), I24 (other acute ischemic heart dis-
eases), and I25 (chronic ischemic heart disease)] and/or more than two outpatient visits per
year due to CHD defined by using data from the HIRA (ICD-10 codes ranged from I20 to I25)
as a principal diagnosis.
To identify the need for RVs, we followed each patient by above procedure codes of PCI
and/or CABG from January 2009 until December 2012. In subjects suffering from multiple cor-
onary events, the first event was considered to be the need for RVs.
Statistical analysis
Continuous and categorical variables are represented as the mean ± standard deviation (SD)
and as percentage (%), respectively. Baseline characteristics among the three group (T2DM
only, recent CHD only, and both T2DM and recent CHD) were compared using one-way anal-
ysis of variance (ANOVA) with Tukey’s method as the post-hoc analysis for continuous vari-
ables and the chi-squared test for categorical variables.
To estimate incidence rates of need for RVs according to the presence of T2DM and/or re-
cent CHD, we calculated actual event rates per 100,000 person-years. We calculated and
Is T2DM a CHD Equivalent?
PLOS ONE | DOI:10.1371/journal.pone.0128627 June 8, 2015 3 / 12
compared the cumulative incidences of need for RVs by the Kaplan–Meier method, and statis-
tical differences among three groups according to the presence of T2DM and/or recent CHD
were compared by the log-rank test. Statistical differences among groups were compared by
calculating the hazard ratios (HRs) and 95% confidence intervals (CIs) for the need for RVs ac-
cording to the presence of T2DM and/or recent CHD. Multivariate Cox proportional hazard
models were applied after adjustment for age and gender. Statistical analyses were conducted
using R version 2.15.3 (R Foundation for Statistical Computing, Vienna, Austria, http://www.
R-project.org). All tests were two-sided, and P<0.05 was considered significant.
Results
A total of 2,168,698 subjects (mean age 61.4 ± 9.9 years, male 52.8%) who had T2DM in 2008
and/or CHD in 2007–2008 (i.e., recent CHD) were enrolled and followed up for the develop-
ment of need for RVs. The total follow-up period was 8,511,148 person-years and the average
follow-up period was 3.92 years. During the study period, 74,343 (3.4%) subjects developed the
need for RVs. The event rate (i.e., need for RVs) in this population was 873.5 per 100,000 per-
son-years. The cohort was classified into three groups based on their status of T2DM and re-
cent CHD at baseline: T2DM without recent CHD (group I, henceforth “T2DM only”), recent
CHD without T2DM (group II, henceforth “recent CHD only”), and recent CHD with T2DM
(group III, henceforth “both T2DM and recent CHD”). The mean age and gender distribution
at baseline are shown in Table 1. The subjects in group III were significantly older and there
was a higher proportion of men (Table 1).
Fig 1A shows the cumulative incidences of need for RVs according to the three groups. The
incidence rates of need for RVs in group I, II and III were 597.9, 1334.6, and 2513.5 per
100,000 person-years, respectively.
Table 2 shows the HRs and 95% CIs of the need for RVs by presence or absence of T2DM
and recent CHD at baseline. Compared to group I, group II and group III showed significantly
higher HRs for need for RVs. Although the significance was slightly lower after adjustment for
age and sex, the adjusted HRs (95% CI) were still significantly higher in group II and group III
than in group I (Table 2).
Fig 1B shows the cumulative incidences of need for RVs as a function of the duration of
T2DM (new-onset T2DM vs. established T2DM) and the presence of recent CHD. The inci-
dence rate of need for RVs in group I with new-onset T2DM, group I with established T2DM
and group II were 422.0, 619.2, and 1334.6 per 100,000 person-years, respectively (Table 3).
The age- and sex-adjusted HR (95% CI) for incident CHD in group I with established T2DM
was 1.36 (1.31–1.42) compared with group I with new-onset T2DM. However, group II sub-
jects still showed significantly higher HRs compared to either type of group I [age- and sex-
Table 1. Baseline characteristics of the study subjects by presence or absence of T2DM and recent CHD.
Group I Group II Group III P value
Number 1,544,892 495,694 128,112 -
Age (years) 60.9±9.9 62.1±10.0 64.5± 8.8 <0.001a
Men (%) 52.7 52.7 54.9 <0.001b
Group I, II and III represent subjects with T2DM only, recent CHD only, and both T2DM and recent CHD, respectively.
aAnalyzed using ANOVA.
bAnalyzed using chi-squared test.
doi:10.1371/journal.pone.0128627.t001
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adjusted HRs (95% CI); 2.95 (2.83–3.06) compared with group I with new-onset T2DM and
2.08 (2.05–2.12) compared with group I with established T2DM, Table 3].
Fig 1. (a) The cumulative incidence of the need for RVs by presence or absence of T2DM and recent CHD (log-rank test, P<0.001 for all comparisons) and
(b) according to the duration of T2DM (new-onset T2DM vs. established T2DM) and recent CHD (log-rank test, P<0.001 for all comparisons).
doi:10.1371/journal.pone.0128627.g001
Table 2. Hazard ratios (HRs) for the need for RVs by presence or absence of T2DM and recent CHD.
Group I Group II Group III
Incidence ratea 597.9 1334.6 2513.5
Crude HR Ref. 2.23 (2.20–2.27) 4.20 (4.11–4.29)
Age- and sex-adjusted HR Ref. 2.14 (2.11–2.18) 3.79 (3.71–3.87)
Crude HR - Ref. 1.88 (1.84–1.92)
Age- and sex-adjusted HR - Ref. 1.79 (1.75–1.82)
aper 100,000 person-years.
Group I, II and III represent subjects with T2DM only, recent CHD only, and both T2DM and recent
CHD, respectively.
P<0.001 for all HRs.
doi:10.1371/journal.pone.0128627.t002
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Table 4 shows the HRs and 95% CIs of need for RVs by presence or absence of T2DM and
recent CHD, defined by the various combinations of hospital discharge databases of the HIRA
(i.e., ICD-10 codes ranged from I20 to I25): more than two outpatient visits per year due to
Table 3. Hazard ratios (HRs) for the need for RVs according to the duration of T2DM and recent CHD.
Group I with new onset T2DM Group I with established T2DM Group II
Incidence ratea 422.0 619.2 1334.6
Crude HR Ref. 1.47 (1.41–1.53) 3.16 (3.04–3.28)
Age- and sex-adjusted HR Ref. 1.36 (1.31–1.42) 2.95 (2.83–3.06)
Crude HR - Ref. 2.15 (2.12–2.19)
Age- and sex-adjusted HR - Ref. 2.08 (2.05–2.12)
aper 100,000 person-years.
Group I, and II represent subjects with T2DM only, and recent CHD only, respectively.
P<0.001 for all HRs.
doi:10.1371/journal.pone.0128627.t003
Table 4. Hazard ratios (HRs) for the need for RVs by presence or absence of T2DM and recent CHD de-
fined using various definitions.
Group I Group II Group III
Recent CHD deﬁned by the ICD-10 codes (I20- I25)
Incidence ratea 597.9 1088.9 2144.3
Crude HR Ref. 1.82 (1.79–1.85) 3.59 (3.50–3.67)
Age- and sex-adjusted HR Ref. 1.76 (1.73–1.80) 3.22 (3.15–3.30)
Crude HR - Ref. 1.97 (1.92–2.02)
Age- and sex-adjusted HR - Ref. 1.83 (1.78–1.88)
Recent CHD deﬁned by the ICD-10 codes (I20 only)
Incidence ratea 597.9 980.8 2051.3
Crude HR Ref. 1.64 (1.61–1.67) 3.43 (3.33–3.53)
Age- and sex-adjusted HR Ref. 1.63 (1.59–1.66) 3.11 (3.03–3.20)
Crude HR - Ref. 2.09 (2.02–2.16)
Age- and sex-adjusted HR - Ref. 1.90 (1.84–1.96)
Recent CHD deﬁned by the ICD-10 codes (I21- I25)
Incidence ratea 597.9 1371.2 2327.8
Crude HR Ref. 2.29 (2.23–2.35) 3.89 (3.75–4.04)
Age- and sex-adjusted HR Ref. 2.10 (2.04–2.15) 3.38 (3.25–3.51)
Crude HR - Ref. 1.70 (1.62–1.77)
Age- and sex-adjusted HR - Ref. 1.64 (1.57–1.72)
Recent CHD deﬁned by the coronary RVs
Incidence ratea 597.9 3357.1 4109.9
Crude HR Ref. 5.61 (5.47–5.75) 6.87 (6.64–7.10)
Age- and sex-adjusted HR Ref. 4.94 (4.82–5.07) 6.01 (5.81–6.22)
Crude HR - Ref. 1.22 (1.17–1.27)
Age- and sex-adjusted HR - Ref. 1.24 (1.19–1.29)
aper 100,000 person-years.
Group I, II and III represent subjects with T2DM only, recent CHD only, and both T2DM and recent
CHD, respectively.
P<0.001 for all HRs.
doi:10.1371/journal.pone.0128627.t004
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CHD, defined using data from the HIRA (ICD-10 codes ranged from I20 to I25) as a principal
diagnosis; and/or codes related with coronary RVs (PCI and/or CABG) at baseline. Regardless
of the definition used for recent CHD, the risk of need for RVs was in the following order, from
lowest to highest: group I, group II and group III.
Fig 2 shows the rate of need for RVs and age-adjusted HRs (95% CI) for need for RVs ac-
cording to the various age groups and sex. Overall, the age-adjusted HRs in the recent CHD
only group for need for RVs (compared with T2DM only group) were lower in women than in
men across all age groups (Fig 2). Regarding the risk according to age, the risk in the T2DM
only group approached that of the recent CHD only group at higher ages in men. For women,
the risk gap between two groups (T2DM only vs. recent CHD only) was smallest in 50–59 year
age group (Fig 2). However, the need for RVs in the T2DM only group increased as age in-
creased in both sexes (Fig 2).
Fig 2. Age-adjusted hazard ratios (HRs) for the need for RVs in subjects with T2DM only vs. recent CHD only in (a) men and (b) women (P<0.001 for
all HRs). aper 100,000 person-years. bRef. group is T2DM only group.
doi:10.1371/journal.pone.0128627.g002
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Discussion
In this nationwide population-based cohort study, we investigated whether diabetic persons
without a recent history of CHD had a recent CHD equivalent risk for need for RVs as non-di-
abetic persons with a recent history of CHD. We found that a prior history of CHD conferred a
higher risk than diabetes alone, and the results depended on sex and age. Our data also demon-
strated a 2-fold increased risk of need for RVs in subjects with both T2DM and recent CHD
compared with subjects with recent CHD only, while their 4-fold increased risk compared with
subjects with T2DM only (Table 2). This finding highlights the importance of aggressive sec-
ondary prevention in patients with coexisting T2DM and CHD.
There are few controversies about the increased incidence of CHD and cardiovascular mor-
bidity and mortality in subjects with T2DM [1–3]. However, it is unclear whether subjects with
T2DM who have not had CHD have an equivalent risk of future CHD compared to those with-
out T2DM who have had a CHD. This is an important issue in light of the aggressive multi-fac-
torial strategies that are conventionally implemented to decrease patient risk factors for CHD
[17]. Furthermore, this concept might not be translated into the Korean population, since the
prevalence and incidence of CHD are significantly lower than in Caucasians [24,25].
Recently, Kim et al. found no relationship between death from CVD and diabetes in three
well-established population-based cohort studies (n = 3,801) in Korea [26]. Based on these
facts, we hypothesized that the need for RVs in Korean subjects with T2DM without CHD
might not be a recent CHD equivalent. To address these questions, we recruited data from
close to the entire Korean population using HIRA data in which the Korean population is
obliged to be registered. Our results indicated that future CHD risk defined by the need for cor-
onary RVs in subjects with T2DM was not a recent CHD equivalent. Furthermore, using HRs,
we found that the magnitude of need for RVs was significantly different depending on the pres-
ence of T2DM and/or recent CHD. To the best of our knowledge, this is the largest study of its
kind performed to date and the first performed exclusively in an Asian population to evaluate
future CHD risk according to the presence of T2DM and/or recent CHD. Our results support
the recent notion that it is both scientifically and clinically inadequate to pursue a one-size-fits-
all strategy for patients with T2DM with regard to cardiovascular risk estimation [17,27].
Results from previous studies on the magnitude of CHD risk associated with diabetes or
prior CHD appear inconsistent. Most recently, Hadaegh et al. reported that new and known
T2DM was a CHD risk equivalent by analyzing data from a population-based cohort study of
2,267 men and 2,931 women over a mean follow-up period of 7.6 years [5]. By contrast, a re-
cent cohort study from 750 Caucasian patients showed that vascular risk was much lower in
patients with T2DM without pre-existing significant coronary artery disease evaluated by coro-
nary angiography [11]. These discrepancies might be attributed to the several factors including
different study designs, diverse study populations, different follow-up duration, and diverse
definition of baseline CHD among studies, as well as the marked advances in medications for
managing multi-factorial risks of CHD such as renin-angiotensin system blockers, statins and
anti-platelet agents. Our analysis differs from many others because we used health information
from the whole population using a nationwide claims database, thereby avoiding selection bias
and providing a large enough sample to examine CHD risk across a broad range of ages. Fur-
thermore, we defined the need for RVs using validated codes for coronary RVs (i.e., PCI and/
or CABG), so there is no doubt about the development of CHD.
In general, diabetes predisposes to incident CHD, and CHD is the leading cause of death
among diabetic patients [28,29]. After MI, diabetics have a more rapid atherosclerotic process
than non-diabetic patients with MI [30]. Similarly, the presence of T2DM conferred a higher
risk of need for RVs in subjects with pre-existing CHD in our study (Table 2). However,
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diabetic patients without recent CHD seemed to have a lower risk of future CHD events de-
fined by the need for RVs than non-diabetic patients with recent CHD, at least in our Korean
population.
Diabetes duration is a potent risk factor for coronary events in patients with T2DM [31,32],
which might explain why studies of those with more advanced diabetes yield higher population
estimates of CHD, whereas those including newly diagnosed patients yield lower estimates
[31,33]. In line with these previous findings, although we could not know the exact duration of
T2DM in our population, established T2DM showed a higher event rate of need for RVs than
new-onset T2DM (Fig 1B). Furthermore, the age- and sex-adjusted HR (95% CI) of established
T2DM for the need for RVs was significantly higher than that of new-onset T2DM (1.36, 95%
CI; 1.31–1.42) (Table 3).
Diabetes raises the risk of CHD to a greater extent in women than in men, although the rea-
son for this difference is not known [24]. Numerous prospective cohort studies demonstrate
that diabetes is a stronger risk factor for CHD in women than in men, with age-adjusted CHD
mortality rates 3- to 7-times higher in diabetic women than in non-diabetic women [3,34], and
2- to 3-times higher in diabetic men than in non-diabetic men [35,36]. When we reanalyzed
the rates of need for RVs and calculated age-adjusted HRs for the need for RVs after stratifying
subjects by age and sex, the risk gaps between subjects with T2DM only and those with recent
CHD only became smaller in women (Fig 2). Our results are in agreement with earlier studies
showing that diabetes raises the risk of CHD to a greater extent in women than in men [9,37],
although it was not as equivalent as recent CHD. Furthermore, the risk gap between the two
groups in women (T2DM only vs. recent CHD only) was smallest in the 50–59 year age group
(i.e., perimenopausal women), while the risk gap between the two groups showed a linear de-
creasing trend with age in men (Fig 2). However, the actual need for RVs in the T2DM only
group increased with increasing age in both sexes (Fig 2). These findings suggest that we should
manage diabetic subjects in a different way based on their sex, age and menopausal state (in
case of women).
Our study has some limitations that should be taken into account. Firstly, we did not in-
clude incident CHD events that were not candidates for coronary RVs (PCI or CABG) or that
were fatal. There remains a possibility that the incident CHD rate in diabetic subjects in this
study was underestimated, as CHD is often asymptomatic in these patients until the onset of
MI or sudden cardiac death [38]. Secondly, the actual previous CHDmight have underesti-
mated, as we ascertained the status of recent CHD during recent two years (i.e., 2007 to 2008).
Moreover, based on the definition of T2DM in this study, we could not guarantee whether
T2DM only group had no previous CHD before 2007. And it is also unclear that this study as-
sessed a risk classification of T2DM against primary or secondary prevention for CHD. Third-
ly, because the HIRA database could not provide the information according to the emergency
of CHD and/or on the evaluated stage of their coronary ischemia, we could not discriminate
between emergent coronary RVs and elective RVs through the database contrary to other pre-
vious study, in which clinical hard endpoints (i.e., MI and/or unstable angina) needed for
emergent coronary RVs were adopted as incident CHD [17]. It might be a major bias in such
clinical settings. Fourthly, we could not adjust for differences in cardiovascular risk factors at
baseline among groups. Although we were unable to adjust for differences in cardiovascular
risk factors at baseline such as lifestyle factors including smoking status and dietary habits, the
presence of hypertension and/or dyslipidemia, and concurrent cardio protective medications
that subjects were taking, multivariate adjustment may not be critical because such adjustments
only reduced the HR for CHD events slightly in previous studies [4,13]. In our study, a sub-
stantial decrease would be required for the difference in risk of need for RVs to become insig-
nificant among groups (Table 2, Table 3 and Table 4). Another important point is the narrow
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width of the confidence intervals in our study (Table 2, Table 3 and Table 4). Finally, the defini-
tion of T2DM based on the use of OADs could be problematic as this could exclude subjects
with undiagnosed diabetes or on diet and exercise without OADs. Furthermore, we did not in-
clude subjects with T2DM on insulin only when defining the prevalence of T2DM, as claims
for insulin are not based on the duration of insulin prescription. However, through this exclu-
sion, type 1 diabetes mellitus (T1DM) might have been excluded as much as possible. Lastly,
the relatively short follow-up period in this study (approximately 4 years) may interfere with
our ability to draw definite conclusions.
The strength of the present study is that it is a large population-based cohort study includ-
ing nearly all Koreans with T2DM and/or recent CHD. We believe a key advantage of the
study is that it uses a primary endpoint derived using the HIRA database in Korea, since HIRA
provides quality-controlled, reliable data.
In conclusion, this analysis of data from the nationwide claims database revealed that
T2DM did not have a recent CHD equivalent risk in the Korean population. These results sug-
gest that an appropriate strategy for the CHD risk stratification in diabetic patients should be
adopted to manage this population.
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